Krystal Biotech (KRYS) Other Non-Current Assets (2018 - 2026)
Krystal Biotech (KRYS) posted quarterly Other Non-Current Assets of $284000.0 for Q2 2026, up 44.16% year-over-year from $197000.0 in Q2 2025, and down 5.33% on a QoQ basis from $300000.0 in Q1 2026.
Krystal Biotech (KRYS) Other Non-Current Assets (2018 - 2026) Analysis & Trends
Krystal Biotech has reported Other Non-Current Assets for 9 years, with the latest figure at $284000.0 in Q2 2026.
- Other Non-Current Assets for Q2 2026 came in at $284000.0, up 44.16% year-over-year; the trailing twelve-month figure through Jun 2026 was $284000.0 (up 44.16% YoY), and the FY2025 annual result was $287000.0, up 24.24% from the prior year.
- Other Non-Current Assets slipped to $284000.0 in Q2 2026, from $300000.0 in the prior quarter.
- Over five years, Other Non-Current Assets peaked at $402000.0 in Q1 2023 and troughed at $126000.0 in Q2 2024.
- A 5-year average of $247500.0 and a median of $247000.0 in 2023 frame the typical range for Other Non-Current Assets.
- The widest annual swing landed in 2022, when Other Non-Current Assets soared 337.84%; it then slumped 55.79% in 2024.
- A 5-year view of Other Non-Current Assets shows it stood at $324000.0 in 2022, then slipped by 18.83% to $263000.0 in 2023, then fell by 12.17% to $231000.0 in 2024, then climbed by 24.24% to $287000.0 in 2025, then fell by 1.05% to $284000.0 in 2026.
- Per Business Quant data, the three most recent Other Non-Current Assets figures were $284000.0 in Q2 2026, $300000.0 in Q1 2026, and $287000.0 in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Other Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 2.31 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 124.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 42.45 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 109.58 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 18,237.65 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 62.96 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 65.13 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 104.44 Mn |
| 10 | Krystal Biotech | 9.83 Bn | 8.99 Bn | 112.79 Mn | 284,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 284,000.00 |
| Mar 31, 2026 | 300,000.00 |
| Dec 31, 2025 | 287,000.00 |
| Sep 30, 2025 | 333,000.00 |
| Jun 30, 2025 | 197,000.00 |
| Mar 31, 2025 | 218,000.00 |
| Dec 31, 2024 | 231,000.00 |
| Sep 30, 2024 | 203,000.00 |
| Jun 30, 2024 | 126,000.00 |
| Mar 31, 2024 | 196,000.00 |
| Dec 31, 2023 | 263,000.00 |
| Sep 30, 2023 | 285,000.00 |
| Jun 30, 2023 | 285,000.00 |
| Mar 31, 2023 | 402,000.00 |
| Dec 31, 2022 | 324,000.00 |
| Sep 30, 2022 | 205,000.00 |
| Jun 30, 2022 | 159,000.00 |
| Mar 31, 2022 | 157,000.00 |
| Dec 31, 2021 | 74,000.00 |
| Sep 30, 2021 | 62,000.00 |